PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page

CDC Advises Early Antiviral Treatment Amidst High Influenza A(H3N2) Activity

by PEPID Newsroom | Mar 28, 2019 | Alerts

Influenza activity, particularly caused by the A(H3N2) virus, remains elevated across the US. The CDC has released a health advisory, reminding clinicians to keep influenza top of mind when diagnosing patients with respiratory illness. The report contains several...

FDA Approves Xofluza, First New Treatment for Influenza in Nearly 20 Years.

by PEPID Newsroom | Oct 31, 2018 | Alerts

Yesterday the U.S. Food and Drug Administration approved Xofluza (balorxavir marhboxil), a new influenza treatment for acute uncomplicated influenza in people age 12 and older who have been symptomatic for no more than 2 days. This new drug, developed by Genentech,...

Recent Posts

  • The Summer Injury Spike: Common ER Visits and How to Prevent Them
  • Men’s Health Month – Closing Gaps in Prevention and Early Detection
  • Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers
  • Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
  • The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved